Abstract
The dramatic increase in survival of extremely premature infants has been associated with a growing population of individuals with neurodevelopmental disabilities. To date, clinical trials of neuroprotective agents in preterm infants have been limited, but new data suggest that erythropoietin might have important neuroprotective effects in these vulnerable infants.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have